A
Arthur M. Feldman
Researcher at Thomas Jefferson University
Publications - 296
Citations - 41891
Arthur M. Feldman is an academic researcher from Thomas Jefferson University. The author has contributed to research in topics: Heart failure & Tumor necrosis factor alpha. The author has an hindex of 79, co-authored 289 publications receiving 40355 citations. Previous affiliations of Arthur M. Feldman include Johns Hopkins University School of Medicine & Valley Hospital.
Papers
More filters
Journal ArticleDOI
Polymorphisms in Adenosine Receptor Genes are Associated with Infarct Size in Patients with Ischemic Cardiomyopathy
Zhonghua Tang,Diamond Ma,Jian-Min Chen,Thomas A. Holly,Robert O. Bonow,Dasgupta A,Terry Hyslop,Purzycki A,Wagner J,Dennis M. McNamara,Tomasz Kukulski,Stanislaw Wos,Eric J. Velazquez,Ardlie K,Arthur M. Feldman +14 more
TL;DR: The results suggest that genetic variants in the adenosine receptor genes may predict the heart's response to ischemia or injury and might also influence an individuals' response to adenosines therapy.
Journal ArticleDOI
Pharmacologic Therapy of Chronic Heart Failure
TL;DR: Neurohormonal manipulation is often ineffective in the pharmacologic therapy of patients with endstage heart failure, therefore other treatment strategies — including the use of inotropic agents to improve pump function and diuretics to control fluid balance are needed.
Journal ArticleDOI
Expression of α-subunits of G proteins in failing human heart : a reappraisal utilizing quantitative polymerase chain reaction
TL;DR: When expressed in molecules of mRNA per microgram of total RNA, there were no differences in the levels of αG i and αG s mRNAs in failing human heart when compared with non-failing controls.
Journal ArticleDOI
Evaluation of a new inotropic agent, OPC-8212, in patients with dilated cardiomyopathy and heart failure.
Arthur M. Feldman,Arthur M. Feldman,Lewis C. Becker,Lewis C. Becker,Michaelene P. Llewellyn,Michaelene P. Llewellyn,Kenneth L. Baughman,Kenneth L. Baughman +7 more
TL;DR: The results of the present phase II study suggest that a larger randomized double-blind placebo study to evaluate the safety and clinical efficacy of this drug is warranted.
Journal ArticleDOI
Constitutive overexpression of phosphomimetic phospholemman S68E mutant results in arrhythmias, early mortality, and heart failure: potential involvement of Na+/Ca2+ exchanger.
Jianliang Song,Erhe Gao,JuFang Wang,Xue-Qian Zhang,Tung O. Chan,Walter J. Koch,Xiying Shang,Jeffrey I. Joseph,Blaise Z. Peterson,Arthur M. Feldman,Joseph Y. Cheung +10 more
TL;DR: It is concluded that constitutive overexpression of S68E mutant was detrimental, both in terms of depressed cardiac function and increased arrhythmogenesis.